Resveratrol is a phytoalexin, stilbenoid compound with antioxidant properties attributable to its bioactive trans-resveratrol content. This study characterized the effects of over-the-counter (OTC) resveratrol nutritional supplements and a HPLC-purified resveratrol formulation, in human transmitochondrial age-related macular degeneration (AMD) retinal pigment epithelial (RPE) patient cell lines. These cell lines, which were created by fusing blood platelets obtained from dry and wet AMD patients with mitochondria-deficient (Rho0) ARPE-19 cells, had identical nuclei (derived from ARPE-19 cells) but different mitochondria that were derived from AMD patients. After resveratrol treatment, the levels of cell viability and reactive oxygen species production were measured. Results demonstrated that treatment with different resveratrol formulations improved cell viability and decreased reactive oxygen species generation in each AMD patient cell line. Although further studies are required to establish the cytoprotective potential of resveratrol under different physiological conditions, this novel study established the positive effects of OTC resveratrol supplements in macular degeneration patient cybrid cell lines in vitro.
Introduction
Resveratrol is a biologically active stilbenoid i.e., a plant polyphenolic compound, and is commonly found in grapes' (Vitis vinifera) skin and seeds, red and white wine, Japanese knotweed (Polygonum cuspidatum), blueberries, cranberries, bilberries, cocoa, pistachios, and peanuts. Compared to the other varieties of wines, red wine has the highest resveratrol content because it is produced by crushing the grapes and leaving the skins in contact with the juice throughout the fermentation process. The Malbec grapes are thicker skinned and therefore have higher concentration of resveratrol compared to the other varieties of red wine grapes [1] .
Resveratrol is a phytoalexin, which is synthesized de novo by numerous plants, including vines, in response to pathogen infection.
Chemically, resveratrol occurs in two isomeric forms namely trans-resveratrol and cis-resveratrol.
Dihydro-resveratrol is a metabolite of both cis-and trans-resveratrol having a different molecular weight.
Trans-resveratrol i.e., 3,5,41-trihydroxy-trans-stilbene, is the predominant bioactive form, which exhibits a broad spectrum of pharmacological properties. The anti-angiogenic activity of resveratrol has been widely studied Resveratrol B1 i.e., the ≥99% HPLC-purified, trans-resveratrol powder, caused no significant difference in cell viability in normal (NL) cybrid (p = 0.7748) ( Figure 1A , Table 2a ) or in wildtype ARPE-19 cells (p = 0.5476) ( Figure 1C , Table 2c ).
In contrast, on average in the AMD cybrids, the resveratrol B1 increased cell viability by 56.65%. Resveratrol Brand 1 (B1)-treated AMD RPE cells had significantly improved cell viability compared to their untreated counterparts (UN) in all AMD cybrids: AMD Patient #1 cybrid-41.5% increase, p = 0.0025 ( Figure 2A , Table 3a ); AMD Patient #2 cybrid-25.5% increase; p = 0.0159 ( Figure 3A , Table 4a ); AMD Patient #3 cybrid-31% increase; p = 0.0003 ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-25.1% increase; p = 0.0294 ( Figure 5A , Table 6a ); AMD Patient #5 cybrid-42% increase; p = 0.0021 ( Figure 6A , Table 7a ); AMD Patient #6 cybrid-21.8% increase; p = 0.0139 ( Figure 7A , Table 8a ); AMD Patient #7 cybrid-59.6% increase; p = 0.0002 ( Figure 8A , Table 9a ); AMD Patient #8 cybrid-33% increase; p = 0.0050 ( Figure 9A , Table 10a ); AMD Patient #9 cybrid-61.1% increase; p = 0.0025 ( Figure 10A , Table 11a ); AMD Patient #10 cybrid-50.9% increase; p = 0.0002 ( Figure 11A , Table 12a ); AMD Patient #11 cybrid-203.4% increase; p = 0.0034 ( Figure 12A , Table 13a ); AMD Patient #12 cybrid-57.3% increase; p = 0.0005 ( Figure 13A , Table 14a ); AMD Patient #13 cybrid-84.3% increase; p = 0.0002 ( Figure 14A , Table 15a ). treated AMD cells; Bar 4-resveratrol B3-treated AMD cells; Bar 5-resveratrol B4-treated AMD cells; Bar 6-resveratrol B5-treated AMD cells; Bar 7-resveratrol B6-treated AMD cells. Data are presented as mean ± SEM; ** p < 0.01. . Effects of resveratrol formulations on cell viability (A) and ROS levels (B) in AMD patient #2. Bar 1-untreated AMD cells; Bar 2-resveratrol B1-treated AMD cells; Bar 3-resveratrol B2treated AMD cells; Bar 4-resveratrol B3-treated AMD cells; Bar 5-resveratrol B4-treated AMD cells; Bar 6-resveratrol B5-treated AMD cells; Bar 7-resveratrol B6-treated AMD cells. Data are presented as mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001. 9 . Effects of resveratrol formulations on cell viability (A) and ROS levels (B) in AMD patient #8. Bar 1-untreated AMD cells; Bar 2-resveratrol B1-treated AMD cells; Bar 3-resveratrol B2treated AMD cells; Bar 4-resveratrol B3-treated AMD cells; Bar 5-resveratrol B4-treated AMD cells; Bar 6-resveratrol B5-treated AMD cells; Bar 7-resveratrol B6-treated AMD cells. Data are presented as mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001; ns = non-significant. 
ROS Levels
Treatment with resveratrol Brand 1 (B1) caused significant reduction in NL RPE cybrid cells (49.15% decrease, p = 0.0006) ( Figure 1B , Table 2b ). Wildtype ARPE-19 cells treated with resveratrol Brand 1 showed lower ROS levels compared to their untreated counterparts (51.76% decrease; p = 0.0006) ( Figure 1D, Table 2d ).
Moreover, resveratrol Brand 1 (B1)-treated AMD RPE cybrid cells had significantly reduced ROS levels (48.75%) compared to their untreated counterparts in all AMD patients: AMD Patient #1 cybrid-37.98% decrease, p = 0.0012 ( Figure 2B, Table 3b ); AMD Patient #2 cybrid-56.1% decrease; p = 0.0002 ( Figure 3B, Table 4b ); AMD Patient #3 cybrid-66.68% decrease, p = 0.0014 ( Figure 4B , Table 5b ); AMD Patient #4 cybrid-55.75% decrease; p = 0.0043 ( Figure 5B, Table 6b ); AMD Patient #5 cybrid-40.36% decrease; p = 0.0012 ( Figure 6B , Table 7b ); AMD Patient #6 cybrid-46.93% decrease; p = 0.0002 ( Figure 7B , Table 8b ); AMD Patient #7 cybrid-41.1% decrease; p = 0.0002 ( Figure 8B , Table 9b ); AMD Patient #8 cybrid-69.13% decrease; p = 0.0003 ( Figure 9B, Table 10b ); AMD Patient #9 cybrid-18.01% decrease; p = 0.0242 ( Figure 10B, Table 11b ); AMD Patient #10 cybrid-39.69% decrease; p = 0.0006 ( Figure 11B , Table 12b ); AMD Patient #11 cybrid-32.84% decrease; p = 0.0002 ( Figure 12B , Table 13b ); AMD Patient #12 cybrid-63.04% decrease; p = 0.0001 ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-66.14% decrease; p = 0.0007 ( Figure 14B , Table 15b ).
Effects of Resveratrol Brand 2 (B2)

Cell Viability
Treatment with resveratrol B2 i.e., capsules containing 250 mg of trans-resveratrol, led to higher cell viability in normal (NL) cybrid cells (23.2% increase, p = 0.0175) ( Figure 1A , Table 1a ) and in wildtype ARPE-19 cells (40% increase, p = 0.0012) ( Figure 1C , Table 2c ).
On average, resveratrol Brand 2 (B2)-treated AMD RPE cells had significantly improved cell viability (56.57%) compared to their untreated AMD cybrids: AMD Patient #1 cybrid-52.2% increase, p = 0.0025; (Figure 2A , Table 3a ); AMD Patient #2 cybrid-39% increase; p = 0.0159; ( Figure 3A , Table 4a ); AMD Patient #3 cybrid-48% increase; p = 0.0014; ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-34.3% increase; p = 0.0139; ( Figure 5A , Table 6a ); AMD Patient #5 cybrid-35.2% increase; p = 0.0021; ( Figure 6A , Table 7a ); AMD Patient #6 cybrid-11.3% increase; p = 0.0498; ( Figure 7A , Table 8a ); AMD Patient #7 cybrid-47.5% increase; p = 0.0002; ( Figure 8A , Table 9a ); AMD Patient #8 cybrid-28.6% increase; p=0.0286; ( Figure 9A , Table 10a ); AMD Patient #9 cybrid-63% increase; p = 0.0025; ( Figure 10A , Table 11a ); AMD Patient #10 cybrid-44.4% increase; p = 0.0002; ( Figure 11A , Table 12a ); AMD Patient #11 cybrid-209% increase; p = 0.0034; ( Figure 12A , Table 13a ); AMD Patient #12 cybrid-19.1% increase; p = 0.0043; ( Figure 13A , Table 14a ); AMD Patient #13 cybrid-103.8% increase; p = 0.0002; ( Figure 14A , Table 15a ).
ROS Levels
Treatment with resveratrol Brand 2 (B2) caused significant reduction in NL RPE cybrid cells (41.71% decrease, p = 0.0006) ( Figure 1B, Table 2b ). ARPE-19 cells treated with resveratrol Brand 2 showed lower ROS levels compared to their untreated counterparts (50.17% decrease; p = 0.0006) ( Figure 1D , Table 2d ).
Furthermore, resveratrol Brand 2 (B2)-treated AMD RPE cells had significantly reduced ROS levels (46.82%) compared to their untreated counterparts in all AMD patients: AMD Patient #1 cybrid-38.43% decrease, p = 0.0012; ( Figure 2B , Table 3b ); AMD Patient #2 cybrid-59.08% decrease; p = 0.0002; (Figure 3B, Table 4b ); AMD Patient #3 cybrid-49.79% decrease; p = 0.0014; ( Figure 4B, Table 5b ); AMD Patient #4 cybrid-56.32% decrease; p = 0.0043; ( Figure 5B, Table 6b ); AMD Patient #5 cybrid-43.83% decrease; p = 0.0012; ( Figure 6B, Table 7b ); AMD Patient #6-47.11% decrease; p = 0.0002; ( Figure 7B , Table 8b ); AMD Patient #7 cybrid-42.84% decrease; p = 0.0002; ( Figure 8B, Table 9b ); AMD Patient #8 cybrid-63.83% decrease; p = 0.0003; ( Figure 9B, Table 10b ); AMD Patient #9 cybrid-24.31% decrease; p = 0.0061; ( Figure 10B , Table 11b ); AMD Patient #10 cybrid-37.53% decrease; p = 0.0006; ( Figure 11B , Table 12b ); AMD Patient #11 cybrid-37.66% decrease; p = 0.0002; ( Figure 12B , Table 13b ); AMD Patient #12 cybrid-56.68% decrease; p = 0.0009; ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-51.29% decrease; p = 0.0007; ( Figure 14B , Table 15b ).
Effects of Resveratrol Brand 3 (B3)
Cell Viability
Treatment with resveratrol B3 i.e., capsules containing 100 mg trans-resveratrol, led to significantly higher cell viability in normal (NL) cybrid cells (35.1% increase, p = 0.0041) ( Figure 1A , Table 2a ) and but not in Wildtype ARPE-19 cells (8.4% increase, p = 0.2619 (ns)) ( Figure 1C , Table 2c ).
Resveratrol Brand 3 (B3)-treated AMD RPE cells had significantly improved cell viability (40.92%) compared to their untreated AMD cybrids: AMD Patient #1 cybrid-32.8% increase, p = 0.0025; (Figure 2A , Table 3a ); AMD Patient #2 cybrid-9.2% increase; p = 0.0357; ( Figure 3A , Table 4a ); AMD Patient #3 cybrid-57.9% increase; p = 0.0014; ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-18.1% increase; p = 0.0498; ( Figure 5A , Table 6a ); AMD Patient #5 cybrid-23.9% increase; p = 0.0021; ( Figure 6A , Table 7a ); AMD Patient #6 cybrid-16.9% increase; p = 0.0294; ( Figure 7A , Table 8a ); AMD Patient #7 cybrid-35.5% increase; p = 0.0003; ( Figure 8A , Table 9a ); AMD Patient #8 cybrid-27.7% increase; p = 0.0095; ( Figure 9A , Table 10a ); AMD Patient #9 cybrid-37.8% increase; p = 0.0025; ( Figure 10A , Table 11a ); AMD Patient #10 cybrid-31.4% increase; p = 0.0002; ( Figure 11A , Table 12a ); AMD Patient #11 cybrid-165.9% increase; p = 0.0034; ( Figure 12A , Table 13a ); AMD Patient #12 cybrid-17.3% increase; p = 0.0095; ( Figure 13A , Table 14a ); AMD Patient #13 cybrid-57.6% increase; p = 0.0002; ( Figure 14A , Table 15a ).
ROS Levels
Treatment with resveratrol Brand 3 (B3) caused significant reduction in NL RPE cells (44.19% decrease, p = 0.0006) ( Figure 1B , Table 2b ). ARPE-19 cells treated with resveratrol Brand 3 showed lower ROS levels compared to their untreated counterparts (49.45% decrease; p = 0.0006) ( Figure 1D , Table 2d ).
On average, the resveratrol Brand 3 (B3)-treated AMD RPE cells had significantly reduced ROS levels (38.5%) compared to their untreated counterparts in all AMD cybrids: AMD Patient #1 cybrid-35.83% decrease, p = 0.0022; ( Figure 2B , Table 3b ); AMD Patient #2 cybrid-45.86% decrease; p = 0.0002; ( Figure 3B , Table 4b ); AMD Patient #3 cybrid-54.96% decrease; p = 0.0014; ( Figure 4B , Table 5b ); AMD Patient #4 cybrid-50.5% decrease; p = 0.0079; ( Figure 5B , Table 6b ); AMD Patient #5 cybrid-32.1% decrease; p = 0.0022; ( Figure 6B , Table 7b ); AMD Patient #6 cybrid-41.44% decrease; p = 0.0002; ( Figure 7B , Table 8b ); AMD Patient #7 cybrid-36.48% decrease; p = 0.0006; ( Figure 8B , Table 9b ); AMD Patient #8 cybrid-44.76% decrease; p = 0.0003; ( Figure 9B , Table 10b ); AMD Patient #9 cybrid-17.15% decrease; p = 0.0095; ( Figure 10B , Table 11b ); AMD Patient #10 cybrid-30.69% decrease; p = 0.0006; ( Figure 11B , Table 12b ); AMD Patient #11 cybrid-34.71% decrease; p = 0.0002; ( Figure 12B , Table 13b ); AMD Patient #12 cybrid-26.04% decrease; p = 0.0013; ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-49.99% decrease; p = 0.0007; ( Figure 14B , Table 15b ).
Effects of Resveratrol Brand 4 (B4)
Cell Viability
Treatment with resveratrol B4 i.e., capsules containing 500 mg red wine complex and an unspecified amount of trans-resveratrol, led to higher cell viability in normal (NL) cybrid cells (50.4% increase, p = 0.0006) ( Figure 1A , Table 2a ) and in wildtype ARPE-19 cells (66.9% increase, p = 0.0012) ( Figure 1C , Table 2c ).
On average, resveratrol Brand 4 (B4)-treated AMD RPE cells had significantly improved cell viability (66.9%) compared to their untreated counterparts in all patients: AMD Patient #1 cybrid-73.9% increase, p = 0.0025; (Figure 2A , Table 3a ); AMD Patient #2 cybrid-28% increase; p = 0.0016; ( Figure 3A , Table 4a ); AMD Patient #3 cybrid-53.4% increase; p = 0.0014; ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-39.8% increase; p = 0.0084; (Figure 5A, Table 6a ); AMD Patient #5 cybrid-67% increase; p = 0.0021; (Figure 6A , Table 7a ); AMD Patient #6 cybrid-47.9% increase; p = 0.0084; (Figure 7A , Table 8a ); AMD Patient #7 cybrid-75.6% increase; p = 0.0003; (Figure 8A , Table 9a ); AMD Patient #8 cybrid-38.2% increase; p = 0.0040; (Figure 9A, Table 10a ); AMD Patient #9 cybrid-70.2% increase; p = 0.0025; (Figure 10A, Table 11a ); AMD Patient #10 cybrid-76.8% increase; p = 0.0002; (Figure 11A , Table 12a ); AMD Patient #11 cybrid-181.9% increase; p = 0.0034; ( Figure 12A , Table 13a ); AMD Patient #12 cybrid-35.4% increase; p = 0.0007; ( Figure 13A , Table 14a ); AMD Patient #13 cybrid-82.1% increase; p = 0.0002; ( Figure 14A , Table 15a ).
ROS Levels
Treatment with resveratrol Brand 4 (B4) caused significant reduction in NL RPE cybrid cells (34.52% decrease, p = 0.0006) ( Figure 1B , Table 2b ). Wildtype ARPE-19 cells treated with resveratrol Brand 4 showed lower ROS levels compared to their untreated counterparts (27.38% decrease; p = 0.0023) ( Figure 1D , Table 2d ).
On average, resveratrol Brand 4 (B4)-treated AMD RPE cells had significantly reduced ROS levels (16.91%) compared to their untreated counterparts in all AMD cybrids: AMD Patient #1 cybrid-22.68% decrease, p = 0.0022; ( Figure 2B , Table 3b ); AMD Patient #2 cybrid-18.26% decrease; p = 0.0040; ( Figure 3B , Table 4b ); AMD Patient #3 cybrid-19.68% decrease; p = 0.0021; ( Figure 4B , Table 5b ); AMD Patient #4 cybrid-14.99% decrease; p = 0.0714; ( Figure 5B , Table 6b ); AMD Patient #5 cybrid-p = 1.0 (non-significant); ( Figure 6B , Table 7b ); AMD Patient #6 cybrid-21.94% decrease; p = 0.0062; ( Figure 7B , Table 8b ); AMD Patient #7 cybrid-25.23% decrease; p = 0.0289; ( Figure 8B , Table 9b ) AMD Patient #8 cybrid-17.06% decrease; p = 0.0047; ( Figure 9B , Table 10b ); AMD Patient #9 cybrid-13.57% decrease; p = 0.4000; ( Figure 10B , Table 11b ); AMD Patient #10 cybrid-p = 0.2667; ( Figure 11B , Table 12b ); AMD Patient #11 cybrid-33.18% decrease; p = 0.0002; ( Figure 12B , Table 13b ); AMD Patient #12 cybrid-11.05% decrease; p = 0.0100; ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-22.14% decrease; p = 0.0007; ( Figure 14B , Table 15b ).
Effects of Resveratrol Brand 5 (B5)
Cell Viability
Treatment with resveratrol B5 i.e., resveratrol from Polygonum cuspidatum root and containing an unspecified amount of trans-resveratrol, resulted in higher cell viability in normal (NL) cybrid (15.9% increase, p = 0.0350) ( Figure 1A , Table 2a ) and in ARPE-19 cells (44.2% increase, p = 0.0012) ( Figure 1C , Table 2c ).
On average, resveratrol Brand 5 (B5)-treated AMD RPE cells had significantly improved cell viability (29.1%) compared to their untreated counterparts in all patients: AMD Patient #1 cybrid-22.3% increase, p = 0.0079; (Figure 2A , Table 3a ); AMD Patient #2 cybrid-25% increase; p = 0.0025; ( Figure 3A , Table 4a ); AMD Patient #3 cybrid-42.7% increase; p = 0.0014; ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-14.8% increase; p = 0.0195; ( Figure 5A , Table 6a ); AMD Patient #5 cybrid-23% increase; p = 0.0021; ( Figure 6A , Table 7a ); AMD Patient #6 cybrid-53.4% increase; p = 0.0084; ( Figure 7A , Table 8a ); AMD Patient #7 cybrid-17.7% increase; p = 0.0003; ( Figure 8A , Table 9a ); AMD Patient #8 cybrid-26.5% increase; p = 0.0095; ( Figure 9A , Table 10a ); AMD Patient #9 cybrid-21.9% increase; p = 0.0025; ( Figure 10A, Table 11a ); AMD Patient #10 cybrid-32.7% increase; p = 0.0002; ( Figure 11A , Table 12a ); AMD Patient #11 cybrid-61.8% increase; p = 0.0034; ( Figure 12A, Table 13a ); AMD Patient #12 cybrid-p = 0.0095 (non-significant); ( Figure 13A, Table 14a ); AMD Patient #13 cybrid-36.6% increase; p = 0.0012; ( Figure 14A , Table 15a ).
ROS Levels
Treatment with resveratrol Brand 5 (B5) caused significant reduction in NL RPE cybrid cells (33.98% decrease, p = 0.0006) ( Figure 1B , Table 2b ). Wildtype ARPE-19 cells treated with resveratrol Brand 5 showed lower ROS levels compared to their untreated counterparts (28.67% decrease; p = 0.0006) ( Figure 1D , Table 2d ).
Resveratrol Brand 5 (B5)-treated AMD RPE cells had significantly reduced ROS levels (22%) compared to their untreated counterparts in all AMD cybrid cells lines: AMD Patient #1 cybrid-31.93% decrease, p = 0.0022; (Figure 2B, Table 3b ); AMD Patient #2 cybrid-24.81% decrease; p = 0.0002; (Figure 3B, Table 4b ); AMD Patient #3 cybrid-p = 0.5074; (Figure 4B, Table 5b ); AMD Patient #4 cybrid-36.55% decrease; p = 0.0079; (Figure 5B, Table 6b ); AMD Patient #5 cybrid-20.35% decrease; p = 0.0238; (Figure 6B, Table 7b ); AMD Patient #6 cybrid-24.91% decrease; p = 0.0007; (Figure 7B , Table 8b ); AMD Patient #7 cybrid-22.02% decrease; p = 0.0379; (Figure 8B, Table 9b ); AMD Patient #8 cybrid-13.5% decrease; p = 0.0303; (Figure 9B, Table 10b ); AMD Patient #9 cybrid-p = 0.4000 (non-significant); ( Figure 10B, Table 11b ); AMD Patient #10 cybrid-24.92% decrease; p = 0.0006; ( Figure 11B , Table 12b ); AMD Patient #11 cybrid-30.16% decrease; p = 0.0002; ( Figure 12B , Table 13b ); AMD Patient #12 cybrid-19.12% decrease; p = 0.0019; ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-25.98% decrease; p = 0.0043; ( Figure 14B , Table 15b ).
Effects of Resveratrol Brand 6 (B6)
Cell Viability
Treatment with resveratrol B6 i.e., resveratrol from Polygonum cuspidatum root and containing an unspecified amount of trans-resveratrol, resulted in higher cell viability in normal (NL) cybrid cells (19.8% increase, p = 0.0221) ( Figure 1A , Table 2a ) and in wildtype ARPE-19 cells (25.9% increase, p = 0.0023) ( Figure 1C , Table 2c ).
On average, resveratrol Brand 6 (B6)-treated AMD RPE cells had significantly improved cell viability (41.45%) compared to their untreated counterparts in all patients: AMD Patient #1 cybrid-46.7% increase, p = 0.0025; (Figure 2A , Table 3a ); AMD Patient #2 cybrid-24.1% increase; p = 0.0016; ( Figure 3A , Table 3a ); AMD Patient #3 cybrid-16.9% increase; p = 0.0175; ( Figure 4A , Table 5a ); AMD Patient #4 cybrid-47.5% increase; p = 0.0084; ( Figure 5A , Table 6a ); AMD Patient #5 cybrid-50.2% increase; p = 0.0021; ( Figure 6A , Table 7a ); AMD Patient #6 cybrid-47.4% increase; p = 0.0106; ( Figure 7A , Table 8a ); AMD Patient #7 cybrid-48.8% increase; p = 0.0003; ( Figure 8A , Table 9a ); AMD Patient #8 cybrid-p = 0.8000 (non-significant); ( Figure 9A , Table 10a ); AMD Patient #9 cybrid-55.9% increase; p = 0.0025; ( Figure 10A , Table 11a ); AMD Patient #10 cybrid-53% increase; p = 0.0002; ( Figure 11A , Table 12a ); AMD Patient #11 cybrid-112.2% increase; p = 0.0034; ( Figure 12A , Table 13a ); AMD Patient #12 cybrid-16.6% increase; p = 0.0027; (Figure 13A, Table 14a ); AMD Patient #13 cybrid-21% increase; p = 0.0093; (Figure 14A, Table 15a ).
ROS Levels
Treatment with resveratrol Brand 6 (B6) caused significant reduction in NL RPE cells (32.55% decrease, p = 0.0006) ( Figure 1B, Table 2b ). ARPE-19 cells treated with resveratrol Brand 6 showed lower ROS levels compared to their untreated counterparts (31.11% decrease; p = 0.0012) ( Figure 1D , Table 2d ).
On average, resveratrol Brand 6 (B6)-treated AMD RPE cells had significantly reduced ROS levels (23%) compared to their untreated counterparts in all AMD cybrid cell lines: AMD Patient #1 cybrid-30.79% decrease, p = 0.0022; (Figure 2B, Table 3b ); AMD Patient #2 cybrid-21.63% decrease; p = 0.0040; (Figure 3B, Table 4b ); AMD Patient #3 cybrid-17.2% decrease; p = 0.0294; ( Figure 4B , Table 5b ); AMD Patient #4 cybrid-26.44% decrease; p = 0.0079; (Figure 5B, Table 6b ); AMD Patient #5 cybrid-16.39% decrease; p = 0.0238; (Figure 6B, Table 7b ); AMD Patient #6 cybrid-19.4% decrease; p = 0.0109; (Figure 7B, Table 8b ); AMD Patient #7 cybrid-31.11% decrease; p = 0.0019; (Figure 8B , Table 9b ); AMD Patient #8 cybrid-28.33% decrease; p = 0.0006; ( Figure 9B, Table 10b ); AMD Patient #9 cybrid-18.38% decrease; p = 0.0159; ( Figure 10B, Table 11b ); AMD Patient #10 cybrid-13.47% decrease; p = 0.0262; ( Figure 11B, Table 12b ); AMD Patient #11 cybrid-33.61% decrease; p = 0.0002; ( Figure 12B, Table 13b ); AMD Patient #12 cybrid-11.33% decrease; p = 0.0317; ( Figure 13B , Table 14b ); AMD Patient #13 cybrid-31.56% decrease; p = 0.0007; (Figure 14B , Table 15b ). Table 16a ,b summarize the effects of treatment with various resveratrol formulations in AMD patients. Decrease.
Discussion
The current study demonstrates the biological effects of resveratrol in AMD RPE transmitochondrial cells in which the mitochondria are derived from AMD patients and the nuclei come from Rho0 ARPE-19 cell lines. Cybrid status and that the cybrids have acquired their mtDNAs from the donor individuals was confirmed using allelic discrimination, Sanger sequencing, and next-generation sequencing. In our recent work [8] [9] [10] [11] , the 'mtDNA damage' that the AMD RPE cybrid cells implicitly carry from the AMD patients has been extensively characterized and various endpoints measured in terms of mitochondrial and cellular health have revealed significant differences including epigenetic alterations, downregulation of mitochondrial transcription and replication genes, mtDNA fragmentation, and reduction in mtDNA copy numbers observed in AMD RPE cybrid cells compared to normal RPE cybrid cells. We found that OTC resveratrol dietary supplements protect AMD RPE transmitochondrial cells against cell death and oxidative stress in vitro, indicating a potential role of resveratrol as a nutritional therapeutic candidate in AMD disease.
Since RPE cell death and oxidative stress are characteristic of AMD disease pathology, in this in vitro study, we sought to compare six different resveratrol brands (with different manufacturers) with regard to their potential in preventing cell death and reducing reactive oxygen species (ROS) in AMD RPE transmitochondrial cell lines. In the transmitochondrial AMD ARPE-19 cybrid cells, since the nuclear content derived from ARPE-19 cells is the same and the cells differ only in the mitochondrial DNA content, which is derived from AMD patients, the idea is that the observed cellular and molecular changes could be attributed to variations in mitochondrial DNA that was obtained from AMD patients. This allows us to examine the mechanisms of retrograde signaling within the cybrid cells and provides an efficient model for in vitro screening of potential therapeutic candidates for AMD. All AMD patients used in this study have been clinically characterized, and genetic and clinical information of all patients is available as partly mentioned in Table 1 . Morphological and functional evaluation of these AMD RPE transmitochondrial cell lines in our previous studies revealed significant mitochondrial and cellular damage as evidenced by apoptotic cell death, higher oxidative stress, low antioxidant content, lower numbers of mitochondria, and higher mtDNA fragmentation in AMD RPE cells [9] [10] [11] [12] [13] . Therefore, AMD RPE transmitochondrial cell lines serve as a good in vitro model to test the effects of resveratrol as a potential over-the-counter candidate for AMD therapy. We tested a wide range of concentrations and chose 1000 µM as the final optimal working concentration for all experiments since it showed the maximum positive effects in pilot experiments. Although all six resveratrol formulations used here produced significant cell rescue effects in AMD cells, the degrees of positive effects differed with each patient. These inter-patient differences could be attributed to demographics with respect to age, type of AMD, and gender. The average age of the AMD patients used in his study was 79.7 ± 1.7 (Mean ± SEM) years. Of the 13 patients, there were eight wet AMD patients and five dry AMD patients; four females and nine males.
We examined cell viability of AMD RPE cells in response to resveratrol administration using the yellow tetrazolium MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) reagent, which is reduced by metabolically active live cells, in part by the action of dehydrogenase enzymes, to generate reducing equivalents such as NADH and NADPH. The resulting intracellular purple formazan is solubilized by DMSO and quantified by spectrophotometry. The chemiluminescence signal produced is proportional to the number of live cells, thereby allowing quantification of changes in the rate of cell viability. We found that resveratrol Brand 1, which was obtained as a ≥99% HPLC-purified trans-resveratrol powder, showed an average increase in cell viability i.e., 56.65% in AMD patient cybrid cell lines compared to their untreated counterparts. Brand 1 was relatively consistent in its potential to increase cell viability in the AMD patient cell lines. This consistency and efficiency of Brand 1 probably could be attributed to its high content of trans-resveratrol, which is the predominant bioactive form of resveratrol and is known to exhibit a broad spectrum of pharmacological properties including antioxidant, anti-cancer, anti-mutagenic, neuroprotective, cardioprotective, anti-inflammatory, and anti-aging activities [14] . In addition to 250 mg of trans-resveratrol, Brand 2 also contained 100 mg of Quercetin (as Quercetin dihydrate), which is a polyphenolic flavonoid commonly found in vegetables and fruits. Quercetin is reported to have a variety of health benefits such as attenuation of anaphylactic reactions, anti-inflammatory, antioxidant, neuroprotective, and anti-cancer activities [15] . This is probably why treatment with resveratrol Brand 2 showed an average increase in cell viability of 56.57%, which was similar to that observed with Brand 1 purified formulation. Brand 3, which provides 100 mg trans-resveratrol from Polygonum cuspidatum root extract and grape (Vitis vinifera) seed and skin extract, showed an average higher cell viability of 40.92% in AMD cells. Brand 4 which contained unspecified amounts of trans-resveratrol from Polygonum cuspidatum root, grape seed, and red wine extract, showed relatively higher average cell viability i.e., 66.9%, among the 13 AMD patient cybrid cell lines studied. Treatment with Brand 6 resveratrol, which was derived from Polygonum cuspidatum root, led to an average increase in viable cell numbers by 41.56%. The manufacturers of Brand 6 did not specify the amount, if any, of trans-resveratrol this formulation contains. Brand 6 resveratrol did not produce any significant increase in live cell number in AMD cells derived from dry AMD patient #8. However, based on our data, one can assume its trans-resveratrol content was similar to those in other formulations. Brand 5 had an average cell viability increase of 29%. Therefore, compared to other formulations, the cell rescue action of Brand 5 was reduced in AMD patient cell lines and no significant effect was observed in ROS levels in AMD cells derived from the wet AMD patients #3 and #9. This may have been because of lower trans-resveratrol content in Brand 5 formulation. Although Brand 5 resveratrol was derived from Polygonum cuspidatum root, no information regarding its trans-resveratrol content, if any, was provided. Of all the patients' cybrid cell lines, resveratrol showed the maximum cell viability increase in AMD cells derived from wet AMD patient #11. The Patient #11 cybrid had more original damage, but they were rescued the most with all of the resveratrol. The untreated cybrid cells had extraordinarily lower cell viability to begin with, but resveratrol improved the cell viability substantially, ranging from 0.75-fold to 2-fold higher than untreated.
These positive effects of resveratrol formulations on cell viability are consistent with previous studies, which have established the role of resveratrol as an anti-apoptotic agent. For instance, Seong et al. demonstrated that resveratrol protects against in vivo ischemia-induced retinal injury by regulating the apoptotic caspase pathway. Resveratrol prevents retinal cell death and mitigates the deleterious effects of retinal injury via downregulation of Caspase-3 and Caspase-8 mRNA transcripts and protein [16] . Resveratrol plays a neuroprotective role in the retina by preventing retinal ganglion cell (RGC) loss via inhibition of the BAX-Caspase-3-dependent apoptotic pathway, attenuation of trauma-induced reactive gliosis, and decreasing the levels of pro-inflammatory cytokines [17] . Lindsey et al. showed that treatment with resveratrol after optic nerve injury protected RGC dendrites by modulating the UPR (unfolded protein response) proteins namely BiP, CHOP, and XBP-1 [18] . Resveratrol alleviates hypoxia-induced apoptosis in retinas in vivo by downregulating Caspase-3 and Caspase-9 genes [19] . Resveratrol's mechanism of cytoprotection varies with the type of insult: Resveratrol exerts its effects by inhibition of caspase activity to mitigate the chemically induced oxidative stress damage; resveratrol regulates tau phosphorylation at Ser422 in response to DNA damage [20] .
As an indicator of ROS levels in cells, we used the cell-permeant 2 ,7 -dichlorodihydrofluorescein diacetate (H2DCFDA), which is a chemically reduced form of fluorescein. Upon cleavage of the acetate groups by intracellular esterases and oxidation, the nonfluorescent H2DCFDA is converted to the highly fluorescent 2 ,7 -dichlorofluorescein (DCF), the intensity of which is directly proportional to ROS levels in cells [21] .
In this study, we tested the effects of resveratrol on ROS levels because mitochondrial ROS production underlies oxidative damage and is crucial in retrograde redox signaling. Intracellular ROS are produced as natural byproducts of oxygen metabolism within organelles such as mitochondria, endoplasmic reticulum, and peroxisomes. In the mitochondria, ROS are generated during ATP formation in oxidative phosphorylation [22] . The free radical theory of aging by Denham Harman attributes aging to free radical accumulation over time [23] . Mitochondrial theory of aging implicates the mitochondria as the primary site of both ROS generation as well as ROS-induced radical damage [24] . Superoxide anion and hydrogen peroxide constitute mitochondrial ROS, and hypoxia, apoptosis, and p53 activation are some of the stimuli that induce mitochondrial ROS production. Several external agents such as pollutants, tobacco, smoke, drugs, xenobiotics, or radiation may act as exogenous stimuli. The deleterious effects of ROS include, but are not limited to, damage to DNA and/or RNA, amino acid oxidation, and lipid peroxidation [25] . To counteract the toxic effects of ROS, the endogenous antioxidant systems come into play-these include superoxide dismutase, catalase, glutathione peroxidase, coenzyme Q, Uric acid, plasma bilirubin, dihydrolipoic acid, and metallothionein. However, diminished antioxidant levels with aging and excessive ROS generation causes redox imbalance resulting in oxidative stress, which is reportedly associated with the pathogenesis of many age-related diseases including AMD [26] . Our recent study has shown elevated mitochondrial superoxide and reduced antioxidant levels in AMD RPE cells [8] .
Resveratrol is known to scavenge free radicals, quench ROS, and upregulate endogenous antioxidants such as superoxide dismutase and catalase [27] . In the present study, the relatively high trans-resveratrol content of Brand 1 and Brand 2 may have accounted for those being the most effective formulations in lowering ROS levels by 48.75% and 46.82%, respectively. in AMD patient cell lines, suggesting their potential to decrease oxidative stress. Brand 3 was the third best resveratrol formulation regarding its ROS lowering potential, causing a 38.5% reduction in ROS levels. Brands 4, -5, and -6 reduced ROS levels by 16.9%, 22%, and 23%, respectively, suggesting their significant but comparatively reduced potential to scavenge ROS in AMD cells. Since the amount of trans-resveratrol in the last three brands was unknown, their lower ROS quenching activity may be attributable to relatively lower trans-resveratrol content. The possible mechanism of action of trans-resveratrol's cytoprotective action is via activation of Sirtuins, which in turn promote longevity in cells thereby delaying aging [15] . Our results are corroborated by previous findings. For example, Xin et al. demonstrated that resveratrol reduces hypoxic stress by decreasing hypoxia-induced upregulation of HIF-1 (Hypoxia-Inducible Factor-1), Trx1 (Thioredoxin 1), and Trx2 (Thioredoxin 2) transcripts in rat retinas [19] . Notably, treatment with resveratrol counteracts ROS-induced cellular injury by inducing various cytoprotective antioxidants and phase 2 enzymes including catalase, superoxide dismutase, glutathione, glutathione reductase, glutathione peroxidase, glutathione S-transferase (GST), and NAD(P)H:quinone oxidoreductase-1 (NOQ1) [28] . Resveratrol reduces hyperglycemia-induced oxidative stress damage by modulating SIRT1 deacetylase activity and the SIRT1/FOXO3a pathway [29] .
Resveratrol formulations tested in the current study produced similar cytoprotective effects in wet and dry AMD patient cell lines. Since the AMD cell lines have damaged AMD mitochondria, we speculate resveratrol exerts its protective effects by improving mitochondrial health and function. This assumption is supported by recent studies that demonstrated that resveratrol exerts its anti-aging effects in zebrafish retina by enhancing mitochondrial quality and growth, suppressing Akt/mTOR pathway, and upregulating Ampk/Sirt1/PGC-1α [30] . Furthermore, systemic treatment in AMD patients that may have modulated the mitochondrial DNA status of patients could certainly influence the AMD cybrid cells' response to resveratrol. However, at this time. we cannot confirm this mechanism.
Cytoprotective effects of resveratrol observed in our study support the results of clinical studies in which resveratrol administration was found to be safe. Clinical trials to test the safety and efficacy of resveratrol for Neovascular AMD were initiated in Europe in 2016. Clinical trials by Brown et al. have demonstrated that resveratrol intake is safe; clinical, biochemical, and hematologic evaluation revealed that resveratrol causes no serious adverse reactions during the study and follow-up visits. Although higher doses of resveratrol i.e., up to 5 mg, caused gastrointestinal discomfort, the symptoms were mild and of severity grade 1 [31] . Apart from safety, development of resveratrol therapeutic will require techniques that increase its bioavailability. In a Phase 1 randomized pilot study by Howells et al., micronized resveratrol was administrated to volunteers since micronization enables enhanced absorption, thereby increasing systemic availability. That study reported micronized resveratrol to have higher C max i.e., maximum serum concentration than reported for equivalent dose of non-micronized resveratrol. Although further clinical investigations are required, the study does suggest micronization as a viable option for development of resveratrol formulation [32] . The Longevinex ® capsules which contain 100 mg of micronized and microencapsulated trans-resveratrol have been successfully used as a nutritional supplement for a long time.
As mentioned above, we used 1000 µM as the final optimal working concentration in this study since 1000 µM resveratrol produced the maximum positive effects in pilot experiments that tested a wide range of resveratrol concentrations in AMD RPE cells. However, additional studies are required to examine the potential of resveratrol at varying concentrations in the in vitro AMD RPE cell model. Furthermore, to shed light on its pharmacokinetics and distribution, further studies with resveratrol metabolites will be required since, upon absorption, resveratrol is rapidly metabolized to resveratrol sulfate and glucuronide conjugates and as dihydroresveratrol-sulfate and dihydroresveratrol-glucuronide.
In conclusion, although further validation, including in vitro studies and randomized, double-blinded, clinical trials, are required to validate the merit of resveratrol as an across the board ocular nutraceutical; our present study is novel as no previous study has examined the role of resveratrol in AMD RPE transmitochondrial cybrid cells, and our study establishes the role of over-the-counter resveratrol formulations in alleviating reactive oxygen species and improving cell viability in AMD transmitochondrial cell lines.
